Intranasal Insulin for Posttraumatic Stress Disorder

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate if intranasal insulin is effective in reducing PTSD symptoms.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: VA Connecticut Healthcare System
• Treatments: Insulin; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Male or female, 21-65 years old

• Current PTSD

• Able to provide written informed consent

Exclusion Criteria:

• Unstable medical condition, clinically determined by a physician

• Diabetes requiring insulin or oral hypoglycemic agents

• Moderate-severe traumatic brain injury

• Current psychotic disorder, bipolar disorder, cognitive disorder in the past 12 months

• Current substance use disorders (except alcohol, tobacco, or cannabis) in the past 3 months

• Changes in doses of psychotropic medications in the past 4 weeks

• Initiation of individual therapy or counseling in the past 4 weeks

• Imminent suicidal or homicidal risk

• Contraindication to Insulin

• History of claustrophobia

• Presence of cardiac pacemaker or other electronic device or ferromagnetic metal foreign bodies in vulnerable positions as assessed by a standard pre-MRI safety screening questionnaire